Brain Protein Expression Profile Confirms the Protective Effect of the ACTH (4-7) PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research with no human subjects
PubMed 34201112 · doi:10.3390/ijms22126179
What was done
Researchers evaluated the effect of the synthetic peptide Semax (ACTH 4-7 PGP) on brain protein expression in a rat model of transient middle cerebral artery occlusion (tMCAO) with reperfusion. Expression of proteins involved in inflammation and cell death (MMP-9, c-Fos, JNK) and neuroprotection/recovery (CREB) was profiled at 24 hours post-tMCAO, and a regulatory network was constructed.
What was found
No numerical data, sample sizes, or p-values are reported in the abstract. Directionally, at 24 hours after tMCAO, Semax administration was associated with upregulation of active CREB in subcortical structures (including the ischemic focus), downregulation of MMP-9 and c-Fos in the adjacent frontoparietal cortex, and downregulation of active JNK in both subcortical and frontoparietal tissues.
Why it matters
The study adds mechanistic protein-level evidence showing how Semax modulates inflammatory, apoptotic, and recovery-associated pathways during acute cerebral ischemia-reperfusion.
Limits
The study is conducted entirely in a rodent model, limiting direct clinical translation to human stroke. The abstract provides no quantitative values, confidence intervals, effect sizes, animal sample size (n), or functional/behavioral neurological recovery outcomes.
Cited by
- supports Semax is a 7-amino-acid peptide studied in Russia that demonstrated improved outcomes following traumatic brain injury and stroke.